Ntrk Fusion Positive Solid Tumors Therapeutics
1. Vitrakvi patent expiration
Treatment: Method of treating cmn, ifs, hgg, dipgs, ptc, soft tissue sarcoma, and spindle cell sarcoma solid tumors exhibiting an ntrk gene fusion in a pediatric patient with an oral solution; Method of treating...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10799505 | BAYER | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
Aug, 2036
(10 years from now) | |
| US8513263 | BAYER | Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors |
Dec, 2029
(3 years from now) | |
| US10172861 | BAYER | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
Nov, 2035
(9 years from now) | |
| US9127013 | BAYER | Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds |
Oct, 2029
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10045991 | BAYER | Methods of treating pediatric cancers |
Apr, 2037
(11 years from now) | |
| US11191766 | BAYER | Methods of treating pediatric cancers |
Apr, 2037
(11 years from now) | |
| US11484535 | BAYER | Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a] pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
Apr, 2037
(11 years from now) | |
| US9782414 | BAYER | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
Nov, 2035
(9 years from now) | |
| US10005783 | BAYER | Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds |
Oct, 2029
(3 years from now) | |
| US10047097 | BAYER | Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds |
Oct, 2029
(3 years from now) | |
| US10813936 | BAYER | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-YL)-pyrazolo[1,5-A]pyrimidin-3-YL)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
Nov, 2035
(9 years from now) | |
| US9676783 | BAYER | Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds |
Oct, 2029
(3 years from now) | |
| US8865698 | BAYER | Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds |
Oct, 2029
(3 years from now) | |
| US9447104 | BAYER | Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds |
Oct, 2029
(3 years from now) | |
| US10285993 | BAYER | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
Nov, 2035
(9 years from now) | |
| US10774085 | BAYER | Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds |
Oct, 2029
(3 years from now) | |
| US11974998 | BAYER | Methods of treatment |
May, 2037
(11 years from now) | |
| US11337967 | BAYER | Methods of treatment |
May, 2037
(11 years from now) | |
| US10668072 | BAYER | Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
Apr, 2037
(11 years from now) | |
| US10137127 | BAYER | Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
Apr, 2037
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 26, 2023 |
| Orphan Drug Exclusivity(ODE-215) | Nov 26, 2025 |
| Orphan Drug Exclusivity(ODE-220) | Nov 26, 2025 |
| Orphan Drug Exclusivity(ODE-221) | Nov 26, 2025 |
Drugs and Companies using LAROTRECTINIB SULFATE ingredient
NCE-1 date: 26 November, 2022
Market Authorisation Date: 26 November, 2018
Dosage: SOLUTION; CAPSULE
How can I launch a generic of VITRAKVI before it's drug patent expiration?
More Information on Dosage
VITRAKVI family patents
